The agent Revlimid (lenalidomide) reduces the need for blood transfusions among patients with lower-risk, non-del (5q) myelodysplastic syndromes who are dependent upon red blood cell transfusions, but are not eligible for erythropoiesis-stimulating agents. These results were recently published in the Journal of Clinical Oncology.

Myelodysplastic syndromes (MDS) refer to a group of diseases in which too many immature blood cells are produced in a patient’s bone marrow.